House Of Representatives Concerned Over Complex Generics
Asks FDA For Documents On Filings And Approvals
The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.
You may also be interested in...
US Energy and Commerce Committee leaders request data on complex generic approvals, guidances, saying additional changes may be needed for faster approvals.
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.